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ABSTRACT: In North America, terrestrial wildlife rabies control is achieved by oral rabies vaccination
programs that principally target mesocarnivores. Success at rabies control in striped skunks (Mephitis
mephitis) has been more limited and may require additional enhancements to existing bait products or
novel bait designs and attractants. We evaluated preference among captive striped skunks for six
different flavors of placebo Ontario Rabies Vaccine Bait (ONRABt) ‘‘Ultralite’’ Baits (Artemis
Technologies, Guelph, Ontario, Canada). Different doses and delivery methods of ONRAB vaccine
were tested for efficacy in a subsequent experiment with the same skunks. Cheese-, egg-, and chicken-
flavored baits were preferred over plain-flavored baits, but a strong preference for a singular flavor was
not observed. Vaccine efficacy of 80–100% was observed among skunks challenged at 335 d
postvaccination across a log range of doses tested by a direct instillation into the oral cavity route,
respectively (109.31010.2 median tissue culture infective doses), in contrast to more-limited efficacy by
bait delivery. Our results extended the duration of ONRAB vaccine efficacy in skunks and suggested
that there may be limited flexibility to alter vaccine titer and volume in novel bait designs for skunks.
Key words: Bait, ONRAB, rabies, skunk, vaccine.
INTRODUCTION
Rabies is one of the world’s most significant
zoonoses, causing an estimated 59,000 cases
annually in humans (Hampson et al. 2015).
While the overwhelming majority of human
rabies deaths are associated with domestic
dogs, wildlife also contributes substantially to
animal and human exposures in many areas of
the world (Christian et al. 2009; Schneider et
al. 2009; Monroe et al. 2016). In the US,
multiple lineages of rabies virus (RABV)
circulating in carnivore wildlife represent
spillover from canine rabies cycles while a
smaller but significant number of lineages
represent spillover from bat rabies cycles
(Kuzmin et al. 2012). Control and prevention
of RABV circulation in reservoir animal
populations is principally achieved by paren-
teral or oral delivery of vaccines.
The National Rabies Management Pro-
gram, administered by the US Department
of Agriculture (USDA) Animal and Plant
Health Inspection Service, Wildlife Services
program, has the mission to control and
eliminate specific RABV variants circulating
in wild mesocarnivores in the US. To manage
and control sylvatic RABV, oral rabies vacci-
nation (ORV) is the primary and most cost-
effective strategy (Rosatte et al. 2007). Dis-
ease management strategies, such as ORV,
immunize wildlife to create a barrier against
RABV transmission by reducing the suscepti-
ble fraction of the population. This is accom-
plished by distribution of vaccine-laden baits
across targeted landscapes for consumption by
target species (Rosatte et al. 2007).
The RABORAL V-RGt product (Merial,
Athens, Georgia, USA) is the only ORV
product currently licensed for use with
raccoons (Procyon lotor) and coyotes (Canis
latrans) in the US and is comprised of a
fishmeal attractant matrix coating a sachet
containing a live-recombinant vaccinia virus
vector expressing an RABV glycoprotein (G)
insert. In the US, target wildlife reservoirs
include raccoons, gray foxes (Urocyon ciner-
eoargenteus), coyotes, and striped skunks
(Mephitis mephitis). While ORV control
strategies utilizing V-RG to target wild canids
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in Texas have been successful (Fearneyhough
et al. 1998; Sidwa et al. 2005), lower levels of
immunity have been observed among raccoon
populations from ORV areas, and the current
V-RG bait product has not been effective in
immunizing captive or free-ranging striped
skunks (Grosenbaugh et al. 2007; Slate et al.
2009). As the raccoon is not the sole vector of
raccoon RABV variant (Guerra et al. 2003), an
effective product to immunize striped skunks
is critically needed to ensure long-term ORV
program success in eliminating raccoon
RABV. A new oral rabies vaccine product
has shown promising results for the control of
rabies in raccoons and striped skunks in
southern Ontario, Canada (Rosatte et al.
2009, 2011). The ONRABt (Artemis Tech-
nologies, Guelph, Ontario, Canada) product is
comprised of a sweet attractant matrix coating
a blister pack containing a live-recombinant
adenovirus vector expressing an RABV G
insert (Yarosh et al. 1996). Although direct
instillation into the oral cavity (DIOC) of the
vaccine constructs used in the V-RG and
ONRAB products have proven immunogenic
and efficacious against RABV challenge in
captive striped skunks (Tolson et al. 1987;
Charlton et al. 1992; Grosenbaugh et al.
2007), the efficacy of vaccine delivery by
current bait products has only been demon-
strated with ONRAB (Brown et al. 2014), and
field success of bait delivery to free-ranging
striped skunks has only been observed using
high-density applications (300 baits/km2) of
ONRAB (Rosatte et al. 2011; Fehlner-
Gardiner et al. 2012; Slate et al. 2014). Thus,
current bait design, size, and attractants for
targeting striped skunks need improvement.
Skunks have smaller jaw morphology and
likely manipulate baits in a different fashion
compared to raccoons (Johnson et al. 2016).
To improve delivery of vaccines to skunks,
research to investigate shape and flavor
preferences and bait manipulation by striped
skunks has been ongoing (e.g., Jojola et al.
2007; Johnson et al. 2016). It is necessary to
test the efficacy of novel bait products for
vaccine delivery, and one potential strategy
may involve reduced bait size and vaccine
volume for improved oral contact in animals
with smaller jaw morphology.
In the past, a variety of bait types and
flavors have been used to target skunks. Toxic
baits have been used to control skunk
populations, but few of these studies have
closely investigated bait flavor or type prefer-
ences. Most studies focusing on skunk bait
preferences are in the context of ORV
applications (e.g., Linhart et al. 1997). Nelson
and Linder (1972) marked 29% of skunks with
dimethylchlortetracycline using chicken eggs
as baits. In a study in Ontario, Canada, baits
made from cubes of beef fat were only
investigated by two free-ranging skunks
(Bachmann et al. 1990), despite observations
in an earlier study where captive skunks ate
similar baits quite readily (Lawson et al.
1987). When given the choice of egg versus
tallow baits, free-ranging skunks showed a
higher selectivity for egg baits (Roy and
Dorrance 1992). In cafeteria-style trials where
baits of various shapes and flavors were
offered, captive skunks were observed to
preferentially consume meat-flavored baits
(Jojola et al. 2007).
We investigated bait interaction and flavor
preferences of captive striped skunks with six
different flavors of placebo ONRAB ‘‘Ultra-
lite’’ Baits (ULBs). Additionally, the efficacy
of varying doses of ONRAB vaccine delivery
by DIOC was tested, in comparison to bait
delivery with a standard dose, against a lethal
RABV challenge.
MATERIALS AND METHODS
Animals, housing, and restraint
We obtained 35 naı¨ve adult striped skunks (15
females, 20 males) from Ruby Fur Farm (New
Sharon, Iowa, USA). During a 14-d quarantine,
we subcutaneously injected sterile passive inte-
grated transponders (PIT) tags (Avid Identifica-
tion System, Norco, California, USA) under
anesthesia for identification (ID). We used 23
skunks for placebo bait flavor-preference trials.
Subsequently, 25 skunks were randomly assigned
to a vaccine efficacy trial and the remaining 10
skunks were assigned to a virus titration study.
Skunks were housed in individual pens (33332.5
m), each with an attached den box, in an open-air
outdoor building for the bait flavor-preference
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and vaccination phases of the study. Skunks were
moved into individual cages (0.73131 m), with a
den box attached, in an Animal Biosafety Level 2
room for challenge and postinfection (PI) moni-
toring. Skunks were fed a daily ration of 100 g of
Mazurit omnivore diet (PMI Nutrition Interna-
tional, St. Louis, Missouri, USA) and water was
provided ad libitum. Skunks were anesthetized
using inhalation delivery of isoflurane gas or an
intramuscular injection of a 5:1 ratio of ketami-
ne:xylazine (10 mg/kg and 2 mg/kg, respectively)
for the purpose of sample collection and inocu-
lation. For isoflurane anesthesia, induction was
accomplished by delivery of 5% isoflurane in
oxygen at 5 L/min over the den box containing the
animal (Bentler et al. 2012), and then animals
were transferred to a cone for maintenance at 2–
3% at 1–2 L/min for sample collection, with
arousal at ambient conditions following removal of
the cone.
Bait flavor-preference trials
We tested six flavors (chicken, egg, cheese,
sweet, fish, and plain) of placebo ONRAB ULBs.
Skunks were offered their standard daily ration in
the afternoon after completion of the daily
morning bait trial. Each possible combination of
flavored baits was presented to skunks in metal
food bowls as a two-choice test, daily, for 15 d.
The sequence of the presentation was randomly
determined, and two animals were tested per
sequence but with the left and right position of
the bait flavors switched (see Supplementary
Material Table S1). At the end of a 5-h bait
presentation window, all bait remains were
removed from individual skunk pens and evaluat-
ed. All bait trials were monitored using motion-
activated trail cameras (Reconyx Silent Image,
Holmen, Wisconsin, USA) and video cameras
(Supercircuits model PC161IR, Supercircuits,
Inc., Austin, Texas, USA; Zodiac model CAM-
Z836IR, Zodiac Light Waves Inc., Ontario,
Canada; Polaris model EZ-380VF, Polaris USA,
Norcross, Georgia, USA). Scores were assigned
for each skunk-bait interaction as follows: animal
does not approach bait (0); animal approaches bait
but does not contact with its mouth (1); oral
manipulation of bait by animal but with no
puncture of the blister pack (2); oral manipulation
and puncture of the blister pack but with
incomplete consumption (3); animal consumed
entire bait, leaving no trace of remains (4).
Camera and video footage were analyzed to verify
scores.
Virus titration
The 92-5A challenge virus is a New York City
dog variant of RABV, most recently passaged in
red foxes (Vulpes vulpes), and was obtained from
the USDA Center for Veterinary Biologics. This
virus was selected for study because it met
regulatory requirements for purity, potency, and
purpose. The neat titer was 107.9 median mouse
intracerebral lethal doses per milli liter
(MICLD50/mL). Virus was diluted using sterile
phosphate-buffered saline supplemented with 2%
fetal bovine serum. Five skunks each were
selected to receive a dose of either 106.9 or 105.9
MICLD50/mL. A baseline blood sample was
collected from each skunk immediately prior to
intramuscular inoculation with 0.5 mL of virus
into each masseter muscle (1.0 mL total). Animals
were monitored daily and, upon display of two or
more clinical signs of rabies, skunks were
anesthetized with an injection of ketamine:xyla-
zine. Under heavy anesthesia, a terminal blood
sample was collected by intracardiac route
immediately prior to administration of euthanasia
solution (pentobarbital sodium and phenytoin
sodium; MWI Veterinary Supply, Boise, Idaho,
USA) by the same route. Tissues harvested during
necropsy of individual skunks included left and
right submandibular salivary glands, brainstem,
and cerebellum.
Vaccine immunogenicity and efficacy trial
After blocking for sex, five skunks each were
randomly assigned to one of the five treatment
groups. Twenty skunks received sham or live
vaccine by DIOC route under light anesthesia,
using a plastic catheter assembled to a stopcock,
with minimal essential media (MEM) supple-
mented with 5% fetal bovine serum (Invitrogen,
Carlsbad, California, USA) as a vaccine diluent.
With corrections for volume, vaccine doses
administered per treatment group were: 0
(MEM only), 1010.2, 109.8, or 109.3 median tissue
culture infective doses (TCID50). Five skunks
were offered an egg-flavored live vaccine bait
containing 1010.2 TCID50 during an 8-h presen-
tation window. Baseline blood samples were
collected prior to vaccination and then postvacci-
nation (PV) on days 30, 60, 90, 180, and 329.
Skunks were challenged with RABV on day 335
PV by intramuscular inoculation with 0.5 mL of
105.9 MICLD50/mL into each masseter muscle
(1.0 mL total). Animals were monitored until day
75 PI, at which point survivors were euthanized.
Upon display of two or more clinical signs of
rabies, skunks were euthanized. All skunks were
sampled postmortem as previously described.
Detection of rabies virus antigen
Brainstem and cerebellum tissues from indi-
vidual skunks were submitted to the Veterinary
Teaching Hospital Diagnostic Lab at Colorado
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State University, Fort Collins, US, for rabies
diagnosis using the direct fluorescent antibody
test (Centers for Disease Control and Prevention
2017).
Detection of rabies virus neutralizing antibodies
Blood samples were centrifuged at 4000 3 G
for 15 min, and serum was separated into
aliquots using sterile technique. Sera were stored
at80 C until shipment to the Rabies Laboratory
at Kansas State University, Manhattan, KS, US.
The sera were processed to titrate the level of
rabies virus neutralizing antibodies (rVNA) by
standard rapid fluorescent focus inhibition test
(Smith et al. 1996), and endpoint titers were
converted to international units per milliliter
(IU/mL) by comparison to a positive control
standard rabies immune globulin containing 2
IU/mL. Titers less than 0.1 IU/mL were consid-
ered rVNA negative.
Detection of rabies virus RNA
Brainstem tissue collected postmortem was
analyzed by PCR to confirm a match to the
challenge virus. Additionally, paired oral swabs
were collected prior to challenge and at day 15 PI,
day 30 PI, and terminally from challenged skunks.
Swabs were stored in MEM and kept on ice packs
immediately following collection and within 5 h
were transferred to storage at80 C until analysis.
We extracted RNA using Trizol reagent (Invitro-
gen) following the manufacturer’s instructions for
brain tissue or with minor modifications for swab
samples. Swab samples in MEM were vortexed
for 15 s and then 500 lL of the solution were
removed for extraction with the lysis buffer step
included. As a positive control and to determine
assay sensitivity, we also extracted the challenge
virus. We converted the RNA extracts to cDNA
copies by reverse transcription, and partial regions
of the RABV G or nucleoprotein (N) genes were
targeted for amplification using a SuperScript III
One-Step RT-PCR with Platinum Taq kit (Invi-
trogen). We amplified a 959-base pair (bp) region
of the G gene from rabies-positive brain tissues
and the neat challenge inoculum using the one-
step RT-PCR kit. A 550-bp region of the N gene
was targeted for the swab samples, but Illustrae
PuReTaqe Ready-To-Goe PCR beads (GE
Healthcare Bio-Sciences, Pittsburgh, Pennsylva-
nia, USA) were used to amplify a 165-bp product
in a hemi-nested PCR. Primers used are listed in
Supplementary Material Table S2. The lowest
concentration of challenge virus detected was
101.9 MICLD50, and we used this dilution as a
positive control in each round of swab screening.
Amplicons produced from swab samples were
cleaned using ExoSAP-IT PCR Product Cleanup
Reagent (Affymetrix, Cleveland, Ohio, USA) and
sequenced in forward and reverse directions using
the respective amplification primers and Big Dye
v.3.1 Cycle Sequencing Kit (Applied Biosystems,
Foster City, California, USA). Sequencing reac-
tions were purified using Sephadex G-50 Fine
(GE Healthcare Bio-Sciences) and then loaded on
an ABI 3500xl Genetic Analyzer (Applied Biosys-
tems). Forward and reverse sequences were
aligned and visually inspected using Sequencher
(Gene Codes Corporation, Ann Arbor, Michigan,
USA).
Statistical analyses
A generalized linear mixed model was used to
analyze the bait interaction score data. Bait flavor
was treated as a fixed effect, with individual skunk
ID and trial day as random effects. A multinomial
model with cumulative logit link function was
used to model the probability of higher interac-
tion scores in association with bait flavor in SAS
v.9.2 (SAS Institute, Cary, North Carolina, USA).
Estimated parameter values and standard errors
are shown. Odds ratios and 95% confidence
intervals were calculated for pair-wise compari-
sons of interaction scores across levels of bait
flavor. For calculation of group geometric mean
rVNA titers, animals with titers less than 0.1 IU/
mL were considered to be 0.05 IU/mL.
RESULTS
Bait flavor-preference trials
A total of 690 individual bait trials were
conducted, split evenly per bait flavor. The
blister packs of baits were punctured during
78% (538/690) of trials, and both punctured
and consumed during 41% (285/688) of trials
(Table 1). The generalized linear mixed model
of bait scores demonstrated an effect of bait
flavor (F5,656¼2.8, P¼0.02) after accounting for
variation among individual skunks (skunk
ID¼9.4363.4) and trial days (trial day¼4.54).
Cheese-, chicken-, and egg-flavored baits
performed better than did sweet and fish
flavors in reference to plain baits (Table 1).
Across 488 trials (of 690 bait trials total) where
skunk behavior with individual baits could be
observed, skunks were documented pinning
baits to the ground in 74% (361/488) of
observations, 8% (38/488) held the bait in
their mouth with their head in an upright
position, less than 1% (1/488) both pinned and
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held the bait with their head in an upright
position, and in 18% (88/488) of observations
the skunk did not interact with the bait.
Virus titration
All challenged skunks developed rabies, and
sequencing of the brain tissue demonstrated
100% identity to the challenge virus. Clinical
signs most commonly included paresis, ataxia,
tremors, and lethargy or irritability. Incuba-
tion periods ranged from 10–17 d (median: 12
d) for skunks receiving 106.9 MICLD50 and
11–22 d (median: 15 d) for skunks receiving
105.9 MICLD50. Between two animals expir-
ing on days 17 and 22, respectively, only one
presented a titer of 0.1 IU/mL on day 15 PI,
and the same animal had a titer of 0.7 IU/mL
upon expiration on day 22 PI. Nine skunks did
not present terminal rVNA titers upon expi-
ration. None of the swab samples collected
prior to challenge, or on day 15 PI (n¼2),
tested positive for RABV RNA. In contrast,
terminal swabs collected from eight rabid
skunks tested positive for RNA. Of two skunks
that tested RNA-negative upon terminal
sampling, one was the animal with an rVNA
titer. A challenge dose of 105.9 MICLD50 was
selected for the vaccine efficacy trial.
Vaccine immunogenicity
Vaccination by DIOC route induced robust
rVNA titers in all but a single treated animal,
and the quantitative level of induction (i.e.,
geometric mean titer per treatment group)
scaled positively with the vaccine dose re-
ceived across the treatment groups (Fig. 1). In
the group of five skunks which were offered
vaccine baits, four skunks ate the baits yet
only two seroconverted. One skunk did not
interact with the bait during the offering, and
rVNA was not detected in this animal at any
time point. No sham-treated animals devel-
oped rVNA at any prechallenge time point.
No adverse reactions to vaccination were
noted during the 335-d observation period
PV. One skunk was found dead on day 293 PV
but tested negative for rabies. This individual
skunk had a history of an abscess on its lower
mandible which had been previously treated,
but an invasive mandibular abscess and an
enlarged spleen were the only remarkable
findings at necropsy.
Vaccine efficacy
Five control (sham-vaccinated) skunks de-
veloped rabies as did 20% (1/5) of skunks in
the lowest-dose DIOC group and 60% (3/5) of
skunks in the bait delivery group (Table 2).
The median incubation period was 12 d
(range: 10–33 d), and sequencing of the brain
tissue from rabid skunks demonstrated 100%
identity to the challenge virus. Among the
DIOC vaccination groups, survival following
lethal challenge was 100% (4/4), 100% (5/5),
TABLE 1. The proportion of trials in which the blister pack was punctured only, or punctured and consumed,
and odds ratio of increasing interaction scores by striped skunks (Mephitis mephitis) during a series of two-choice
trials evaluating six flavors of placebo ONRABt ‘‘Ultralite’’ Baits (Artemis Technologies). The plain flavor served
as the reference level for comparison of the odds ratios. — ¼ not applicable; CI ¼ confidence interval.
Bait flavor
Total no.
of trials
Percent
punctured only
Total no.
of trials
Percent punctured
and consumed
Odds ratio
(95% CI)
Cheese 115 81.7 114a 43.9 2.6 (1.4–4.6)
Chicken 115 80.0 114 43.9 2.5 (1.4–4.5)
Egg 115 80.9 115 46.1 2.3 (1.3–4.2)
Sweet 115 80.0 115 39.1 1.7 (1.0–3.1)
Fish 115 76.5 115 37.4 1.6 (0.9–2.8)
Plain (reference) 115 68.7 115 38.3 —
Total 690 78.0 688 41.4 —
a One trial involving a cheese and chicken bait were treated as missing data, as it could not be determined which bait was completely
consumed.
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and 80% (4/5), or 93% (13/14) overall among
DIOC treatment groups (Table 2). In the bait
group, survival was 40% (2/5) among skunks
offered baits but 50% (2/4) among skunks that
had consumed baits (i.e., one skunk did not
interact with a bait during the 8-h presenta-
tion).
None of the sham-vaccinated skunks dem-
onstrated rVNA at any time point leading up
to challenge (Table 3), but one skunk
demonstrated a titer of 3.4 IU/mL on day 15
PI, immediately prior to expiration on day 16
PI with a titer of 5.0 IU/mL. Two other
control skunks, which expired on days 19 and
33 PI, did not demonstrate titers on day 15 PI,
and only one had a marginal titer (0.1 IU/mL)
upon expiration. The skunk that did not
interact with a bait and a single DIOC-
vaccinated skunk both succumbed to rabies
and did not demonstrate rVNA at any time
point nor upon terminal sampling (Table 3).
Between two skunks that consumed baits yet
succumbed to challenge, one did not demon-
strate rVNA prior to challenge but presented a
terminal rVNA titer of 2.2 IU/mL, and the
other displayed an rVNA response of 0.2 IU/
mL on day 60 PV only and then presented a
titer of 3.1 IU/mL upon expiration. Converse-
ly, between the two skunks which consumed
baits and survived challenge, one did not
present an rVNA response until after chal-
lenge, and the other demonstrated a consis-
tent but low titer prechallenge (0.2–0.4 IU/
mL) and anamnestic response to challenge.
The geometric mean titers of each treatment
group except the sham-vaccinated animals
demonstrated an anamnestic rVNA response
at day 15 PI, which declined by day 75 PI
(Fig. 1). None of the oral swab samples
collected prior to challenge or on day 15 PI
(n¼18) tested positive for RABV RNA. A
single swab sample tested positive on day 30
FIGURE 1. The geometric mean rabies virus neutralizing antibody (rVNA) titers of each treatment group of
striped skunks (Mephitis mephitis) vaccinated with ONRABt (Artemis Technologies) and challenged with rabies
virus on day 335 postvaccination. DIOC¼direct instillation into the oral cavity; BAIT¼bait delivery.
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PI from a skunk that developed rabies and
expired on day 33 PI. Among terminal swabs
from nine rabid skunks, six tested RNA-
positive. The three terminal swabs from rabid
skunks that tested RNA-negative were from
skunks with terminal titers of 2.2, 3.1, and 5.0
IU/mL. All terminal swabs from 15 skunks
surviving to day 75 PI tested negative for
RNA.
DISCUSSION
Skunks are omnivores and consume a wide
variety of prey and forage items. The placebo-
bait interaction trials revealed a preference for
cheese, chicken, and egg flavors when com-
pared to plain baits, but strong preference for
a single flavor was not observed. Similar
consumption rates were observed for ULB
and spherical baits in comparing the results of
this study with a similar study utilizing the
same cohort of captive skunks and over a
standardized presentation period (Johnson et
al. 2016), suggesting a lack of shape prefer-
ence between oblong and spherical bait
presentations. Many factors can influence
what makes a bait effective at targeting
skunks. Nevertheless, factors such as season,
host density, habitat use, and nontarget
species competition also affect application
strategy on the landscape and subsequent
uptake rates by free-ranging target animals.
Thus, field testing of flavor candidates iden-
tified in the captive study will be important.
High resistance to challenge was observed
in skunks vaccinated by the DIOC route. One
early study reported 100% (8/8) survival of
skunks vaccinated via DIOC with 108.1
TCID50 of a precursor to the ONRAB vaccine
compared to 100% (8/8) mortality of control
animals when challenged 90 days PV (Charl-
ton et al. 1992). A later study observed 100%
(23/23) survival of skunks vaccinated via
DIOC with 1010.3 TCID50 of commercial
ONRAB (AdRG1.3) vaccine, 81% (25/31)
survival of animals consuming a ULB con-
taining 1010.3 TCID50 of commercial ONRAB,
and 100% (10/10) mortality of control animals
when challenged 247 d PV (Brown et al.
2014). This study further confirms and
extends the immunogenicity and efficacy of
ONRAB vaccine by a DIOC route in skunks
challenged 335 d PV. At vaccine doses of 109.8
and 1010.2 TCID50 by DIOC, 100% (9/9)
survival was observed, with slightly lower
survival in the 109.3 TCID50 group. Despite
the low sample sizes in this study, similar
efficacy was observed with DIOC doses that
were approximately one log lower than the
bait doses used in Brown et al. (2014). It has
been suggested that the vaccine dose for bait
delivery should be approximately one log
higher than the lowest dose efficacious by
DIOC route (World Organisation for Animal
Health 2016). Observations in this and earlier
studies suggest that there may not be sub-
stantial flexibility to lower the current vaccine
dose (about 1010 TCID50) of ONRAB for bait
TABLE 2. Summary percentages of striped skunks (Mephitis mephitis) that seroconverted and were protected
when vaccinated with ONRABt (Artemis Technologies) by two delivery routes and challenged with rabies virus
335 d postvaccination.a
Group
No.
of skunks
Vaccine
route
Vaccine dose
(log TCID50)
Percent
seroconvertedb
Percent surviving
rabies challengec
A 5 DIOC 10.2 100 100
B 5 DIOC 9.8 100 100
C 5 DIOC 9.3 80 80
D 5 BAIT 10.2 40 40
E 5 DIOC Sham 0 0
a TCID50 ¼median tissue culture infective doses; DIOC ¼ direct instillation into the oral cavity; BAIT ¼ bait delivery.
b Percent of animals in group with a level of rabies virus neutralizing antibody greater than or equal to 0.2 IU/mL at any time point prior
to challenge.
c Percent surviving to 75 d postinfection.
128 JOURNAL OF WILDLIFE DISEASES, VOL. 54, NO. 1, JANUARY 2018
presentation. Greater sample sizes are needed
for robust determination of the minimum
protective dose of ONRAB by DIOC route in
striped skunks.
In contrast to Brown et al. (2014), we
observed low efficacy by bait delivery. In both
studies, the titers of vaccine used in the baits
and subsequent doses delivered were similar.
In Brown et al. (2014), 93% (28/30) of skunks
entirely or mostly consumed the blister packs
of baits whereas the remaining 7% (2/30)
presented some evidence of blister pack
chewing. In this study, 60% (3/5) of skunks
entirely or mostly consumed the blister packs
of baits whereas 20% (1/5) presented some
evidence of blister pack chewing and 20% (1/
5) did not interact at all with the bait. Seasonal
differences may have been a factor in the
reduced level of interaction observed among
skunks in the current study (i.e., bait offering
TABLE 3. Rabies virus neutralizing antibody (rVNA) titers for individual striped skunks (Mephitis mephitis)
vaccinated with ONRABt (Artemis Technologies), and their fate following infection with rabies virus.a
Skunk
ID Sex
Vaccine
route
Vaccine
dose
(log
TCID50)
rVNA (IU/mL) Fate
(incubation
period,
days)d
Day
0
Day
30
Day
60
Day
90
Day
180
Day
329
Day
350b
Day
365
Day
410 Terminalc
1-279 F DIOC 10.2 ,0.1 31.0 34.0 22.0 13.7 11.0 27.5 22.0 18.5 S
6-614 F DIOC 10.2 ,0.1 131.0 149.0 120.0 90.0 250 180 80.0 70.0 S
8-821 F DIOC 10.2 ,0.1 111.0 31.0 34.0 13.0 — — — — n.d. Ne
3-076 M DIOC 10.2 ,0.1 77.0 149.0 149.0 38.0 67.5 60.0 42.0 68.5 S
6-881 M DIOC 10.2 ,0.1 59.0 77.0 31.0 33.0 54.0 61.5 56.5 27.0 S
3-882 F DIOC 9.8 ,0.1 53.0 53.0 45.0 33.0 60.0 67.5 54.0 47.0 S
3-271 F DIOC 9.8 ,0.1 30.0 20.0 7.0 5.4 11.5 24.0 22.0 17.5 S
7-065 M DIOC 9.8 ,0.1 0.5 0.9 0.6 0.2 0.4 4.8 4.4 2.5 S
5-839 M DIOC 9.8 ,0.1 34.0 28.0 31.0 31.0 36.5 10.0 29.5 29.5 S
6-609 M DIOC 9.8 ,0.1 28.0 8.0 4.5 3.4 5.5 9.0 5.4 4.4 S
1-822 F DIOC 9.3 ,0.1 12.5 6.9 8.6 11.3 9.2 27.5 16.0 13.7 S
7-879 F DIOC 9.3 ,0.1 ,0.1 ,0.1 ,0.1 ,0.1 ,0.1 — — — ,0.1 D (12)
1-041 M DIOC 9.3 ,0.1 31.0 20.0 26.0 13.0 14.0 31.5 27.0 17.5 S
8-120 M DIOC 9.3 ,0.1 20.0 12.0 8.6 7.4 11.5 14.0 18.5 17.0 S
8-593 M DIOC 9.3 ,0.1 12.5 10.0 7.6 5.0 14.0 13.5 19.5 18.5 S
5-013 F DIOC Sham ,0.1 ,0.1 ,0.1 ,0.1 ,0.1 ,0.1 ,0.1 ,0.1 — 0.1 D (33)
2-380 F DIOC Sham ,0.1 ,0.1 ,0.1 ,0.1 ,0.1 ,0.1 — — — n.d. D (11)
5-591 M DIOC Sham ,0.1 ,0.1 ,0.1 ,0.1 ,0.1 ,0.1 — — — ,0.1 D (10)
9-119 M DIOC Sham ,0.1 ,0.1 ,0.1 ,0.1 ,0.1 ,0.1 ,0.1 — — ,0.1 D (19)
3-589 M DIOC Sham ,0.1 ,0.1 ,0.1 ,0.1 ,0.1 ,0.1 3.4 — — 5.0 D (16)
8-827f F BAIT 10.2 ,0.1 ,0.1 ,0.1 ,0.1 ,0.1 ,0.1 — — — ,0.1 D (11)
7-857 M BAIT 10.2 ,0.1 ,0.1 ,0.1 ,0.1 ,0.1 ,0.1 0.2 0.3 0.1 S
6-856 M BAIT 10.2 ,0.1 0.3 0.2 0.2 0.2 0.4 24.0 22.0 11.3 S
1-261 M BAIT 10.2 ,0.1 ,0.1 ,0.1 ,0.1 ,0.1 ,0.1 — — — 2.2 D (10)
2-337 M BAIT 10.2 ,0.1 ,0.1 0.2 ,0.1 ,0.1 ,0.1 — — — 3.1 D (12)
a TCID50 ¼ median tissue culture infective doses; F ¼ female; M ¼male; DIOC ¼ direct instillation into the oral cavity; BAIT ¼ bait
delivery; n.d.¼ not determined.
b Time point is day 15 postinfection.
c Terminal titers for animals surviving to day 75 postinfection are listed under day 410.
d S¼ survived to day 75 postinfection and tested rabies negative; N¼nonspecific death prior to challenge and tested rabies negative; D¼
succumbed and tested rabies positive.
e This animal was found dead on day 293 postvaccination.
f Animal did not interact with the bait during offering period.
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in July versus October in the prior study). The
8-h offering period used in this study appears
adequate, based on observations in Brown et
al. (2014) where all skunks had consumed or
interacted with baits within 1.5 h. In the
Brown et al. (2014) study, food was withheld
from animals for 24 h prior to the bait
presentation whereas in this study food was
withheld from animals for about 18 h prior to
the bait presentation, yet the animals in our
study had likely consumed their daily ration
on the previous day. A slightly lower propor-
tion of skunks that consumed baits serocon-
verted with rabies antibodies in the current
study, although most antibody measurements
were not directly comparable due to the
different test methodology used and low
power for comparison in the current study.
Subsequent laboratory evaluations of the egg-
flavored matrix used in this study revealed
virucidal properties of the formulation, which
may have interfered with the immunogenicity
and efficacy of the vaccine bait used in this
study. When coupled with a longer interval
between vaccination and challenge, these
factors may potentially explain the lower bait
efficacy observed in this study. Furthermore,
the serologic response data of the skunks
vaccinated by bait were inconsistent with the
efficacy results in this study, where vaccina-
tion responders and nonresponders both
succumbed and survived respectively, yet the
phenomenon is not unique to this dataset
(Moore et al. 2017).
Skunks continue to present challenges for
ORV programs. In the context of US ORV
objectives, vaccination of skunk populations
may be necessary to achieve elimination of
raccoon RABV, given levels of spillover into
this key secondary host (Guerra et al. 2003;
Wallace et al. 2014). It seems unlikely that the
dose of vaccine used in ONRAB baits for
skunks can be reduced substantially. Howev-
er, slight reductions in the volume of vaccine
carried by the blister packs, which do not
compromise vaccine dose, may still be one
strategy for consideration in an attempt to
alter the manipulation behavior of skunks for
improved contact of the vaccine with the oral
mucosa. Nevertheless, field testing of modi-
fied bait designs is still critical to evaluate the
success in uptake and immune induction by
free-ranging skunks.
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